CBLN2 Polyclonal Antibody, ALEXA FLUOR® 594 Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Rat

Predicted Reactivity

  • Human
  • Mouse
  • Dog
  • Cow
  • Pig
  • Horse
  • Rabbit
Overview
Catalog # bs-11815R-A594
Product Name CBLN2 Polyclonal Antibody, ALEXA FLUOR® 594 Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Rat
Predicted Reactivity Human, Mouse, Dog, Cow, Pig, Horse, Rabbit
Specifications
Conjugation ALEXA FLUOR® 594
Host Rabbit
Source KLH conjugated synthetic peptide derived from human CBLN2
Immunogen Range 151-224/224
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Subcellular location Cell membrane
Synonyms A730004O05; Cbln2; CBLN2_HUMAN; Cerebellin 2; Cerebellin 2 precursor; Cerebellin-2; OTTHUMP00000163726.
Background Cerebellin (CER), which was originally isolated from rat cerebellum, is a hexadecapeptide derived from a larger precursor Cerebellin 1, also designated precerebellin 1 or Cbln1. Four propeptides, Cerebellin 1, Cerebellin 2 (Cbln2), Cerebellin 3 (Cbln3), and Cerebellin 4 (Cbln4), comprise the precerebellin subfamily within the C1q protein family. Cerebellin family members act as transneuronal regulators of synapse development and synaptic plasticity in various brain regions. CER and it metabolite des-Ser1-cerebellin are also expressed in several extra-cerebellar tissues, including adrenal gland. Cerebellin 1, 2 and 3 assemble into homomeric and heteromeric complexes, thereby influencing each other?s degradation and secretion. Cerebellin 3 is not able to form homomeric complexes, and can only be secreted upon forming a heteromeric complex with Cerebellin 1. Decreased concentrations of CER has been found in the brain of patients with olivopontocerebellar atrophy (OPCA) and Shy-Drager syndrome, suggesting a role for CER in the pathology of these diseases.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200